Helicobacter pylori infection and serum adiponectin

Helicobacter

Volumn 18, Issue 4, 2013, Pages 321-322

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Zavos, Christos ^a   Pyrrou, Nikoleta ^a   Tantsi, Nikoleta ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMPICILLIN; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; GLUCOSE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INSULIN; NORFLOXACIN; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; DYSPEPSIA; FATTY ACID OXIDATION; GASTROINTESTINAL ENDOSCOPY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HELICOBACTER INFECTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LETTER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METABOLIC DISEASES;

HELICOBACTER PYLORI;

EID: 84879425847     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12059     Document Type: Letter

References (5)

1. Ando T, Ishikawa T, Takagi T, et al. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter 2013;18:158-64.
2. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2010;12:365-83.
3. Polyzos SA, Kountouras J, Papatheodorou A, et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013;62:121-6.
4. Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008;22:2416-26.
5. Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011;16:79-88.